Are there published papers on Cobimetinib

According to the National Cancer Institute (NCI), Cobimetinib is a targeted therapy drug that works as a MEK inhibitor, which means it blocks certain proteins that can cause cancer cells to grow.

The FDA has approved Cobimetinib for specific uses:

1. According to FDA approvals, Cobimetinib is approved in combination with vemurafenib (Zelboraf) for treating adults with melanoma that:

• Has spread or cannot be removed by surgery
• Has a specific genetic mutation called BRAF V600E or V600K

The National Comprehensive Cancer Network (NCCN) Guidelines include Cobimetinib as part of their treatment algorithms for:

• BRAF V600-mutated melanoma (in combination with vemurafenib)
• Some histiocytic neoplasms (rare blood disorders)

It's important to note that:

1. This medication requires a prescription and careful monitoring by your healthcare team
2. Your doctor needs to test your tumor for specific genetic mutations before prescribing this medication
3. Regular monitoring is needed while on this treatment

Always consult with your healthcare provider about whether Cobimetinib might be appropriate for your specific situation, as they can evaluate your individual case and medical history.

Would you like me to provide more specific information about any aspect of Cobimetinib, such as its side effects or how it's taken?